Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: A potential risk of suicide associated with liraglutide or semaglutide treatments has recently emerged. Therefore, we decided to investigate the reporting probability of suicidal events among glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Methods: A retrospective pharmacovigilance study of the European Pharmacovigilance database was conducted for the period from 1 January 2018 to 10 July 2023. Disproportionality analyses (reporting odds ratio, ROR) were performed to assess the reporting probability of suicidal events among GLP-1 RAs. Results: A total of 230 reports of suicidal events were identified. The most reported GLP-1 RA was liraglutide (38.3%), followed by semaglutide (36.5%) and dulaglutide (16.1%). The most reported events were suicidal ideation (65.3%) and suicide attempt (19.5%). Disproportionality analysis found a higher reporting probability of suicidal events for semaglutide than dulaglutide (ROR, 2.05; 95%CI, 1.40–3.01) and exenatide (ROR, 1.81; 95%CI, 1.08–3.05). In the same way, liraglutide was associated with a higher reporting probability of suicidal events than dulaglutide (ROR, 3.98; 95%CI, 2.73–5.82) and exenatide (ROR, 3.52; 95%CI, 2.10–5.92). On the contrary, a lower reporting probability was found for semaglutide than liraglutide (ROR, 0.51; 95%CI, 0.38–0.69). Conclusions: Suicidal events were mostly reported with semaglutide and liraglutide, which were also associated with significantly higher reporting probabilities compared to other GLP1 RAs. Although this study provides the reporting frequencies of suicide-related events with GLP-1 RAs, establishing causality requires further investigation, which will probably be addressed by the Pharmacovigilance Risk Assessment Committee of the European Medicine Agency in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“Beyond hypoglycaemic, endocrine, and cardiovascular effects, several decades of research have also shown the extended actions of GLP-1 RAs, which include decelerated gastric emptying and a reduction in food intake and body weight [4].”
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510 · cited 2×
“A possible mechanism explaining the risk of suicidal events with GLP-1 RAs is re-lated to their action in the hypothalamus [5] since the hyperactivity of the hypothalamic– pituitary–adrenal axis has been associated with suicidal behaviours [22].”
Association of semaglutide with risk of suicidal ideation in a real-world cohort
Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Nature Medicine · doi:10.1038/s41591-023-02672-2 · Cited by 248
McIntyre, R. S., Mansur, R. B., Rosenblat, J. D., & Kwan, A. T. H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2295397 · Cited by 126
O'Neil, P. M., Aroda, V. R., Astrup, A., Kushner, R., Lau, D. C. W., Wadden, T. A., Brett, J., Cancino, A., Wilding, J. P. H., & groups, O. B. O. T. S. A. C. A. –. L. E. I. I. W. A. W. D. (. S. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12963 · Cited by 115
Kim, Y.-K., Kim, O. Y., & Song, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01270 · Cited by 109
Zhang, F., Chen, Z., Wu, D., Tian, L., Chen, Q., Ye, Y., Chen, W., Wu, X., Wu, P., Yuan, W., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103382 · Cited by 54
Zhang, Y. L., Zhou, C., Li, X. F., Yang, M. N., Tao, L., Zheng, X. Y., & Jia, Y. S. (2019) · Obesity Science & Practice · doi:10.1002/osp4.342 · Cited by 49 · cited 1×
“From our research, we excluded the following molecules: albiglutide, which was actually withdrawn from the European market due to commercial reasons [50], and beinaglutide, which his authorized only in the United States [51] and China [52].”
Research works printed but not linked: 33
- Romera, 2022, Glucagon-like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations, Diabetes Ther., 13, 389, 10.1007/s13300-021-01198-5 · DOI
- Chiappini, S., Vickers-Smith, R., Harris, D., Pelletier, G.D.P., Corkery, J.M., Guirguis, A., Martinotti, G., Sensi, S.L., and Schifano, F. (2023). Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset. Pharmaceuticals, 16. · DOI
- Chen, 2023, Postmarket Safety Profile of Suicide/Self-Injury for GLP-1 Receptor Agonist: A Real-World Pharmacovigilance Analysis, Eur. Psychiatry, 66, e99, 10.1192/j.eurpsy.2023.2474 · DOI · Paper page
- Lucas, S., Ailani, J., Smith, T.R., Abdrabboh, A., Xue, F., and Navetta, M.S. (2022). Pharmacovigilance: Reporting Requirements throughout a Product’s Lifecycle. Ther. Adv. Drug Saf., 13. · DOI
- Kang, 2012, Anti-Obesity Drugs: A Review about Their Effects and Safety, Diabetes Metab. J., 36, 13, 10.4093/dmj.2012.36.1.13 · DOI · Paper page
- Rodgers, 2012, Anti-Obesity Drugs: Past, Present and Future, Dis. Model. Mech., 5, 621, 10.1242/dmm.009621 · DOI · Paper page
- Blonde, 2009, The Safety and Efficacy of Liraglutide with or without Oral Antidiabetic Drug Therapy in Type 2 Diabetes: An Overview of the LEAD 1-5 Studies, Diabetes Obes. Metab., 11, 26, 10.1111/j.1463-1326.2009.01075.x · DOI · Paper page
- Wisłowska-Stanek, A., Kołosowska, K., and Maciejak, P. (2021). Neurobiological Basis of Increased Risk for Suicidal Behaviour. Cells, 10. · DOI · Paper page
- Anderberg, 2017, Glucagon-like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight, Diabetes, 66, 1062, 10.2337/db16-0755 · DOI · Paper page
- Chivite, 2021, Central Serotonin Participates in the Anorexigenic Effect of GLP-1 in Rainbow Trout (Oncorhynchus mykiss), Gen. Comp. Endocrinol., 304, 113716, 10.1016/j.ygcen.2021.113716 · DOI
- Rossi, C., Ruggiero, R., Sportiello, L., Pentella, C., Gaio, M., Pinto, A., and Rafaniello, C. (2022). Did the COVID-19 Pandemic Affect Contrast Media-Induced Adverse Drug Reaction’s Reporting? A Pharmacovigilance Study in Southern Italy. J. Clin. Med., 11. · DOI
- Ruggiero, 2022, Capillary Leak Syndrome Following COVID-19 Vaccination: Data from the European Pharmacovigilance Database Eudravigilance, Front. Immunol., 13, 956825, 10.3389/fimmu.2022.956825 · DOI
- Sher, 2023, Suicide: An Overview for Clinicians, Med. Clin. N. Am., 107, 119, 10.1016/j.mcna.2022.03.008 · DOI
- Iwatate, 2023, Association of Obesity, Suicide Behaviors, and Psychosocial Wellness Among Adolescents in the United States, J. Adolesc. Health, 72, 526, 10.1016/j.jadohealth.2022.11.240 · DOI
- Sarkar, 2014, Diabetes Mellitus and Suicide, Indian. J. Endocrinol. Metab., 18, 468, 10.4103/2230-8210.137487 · DOI
- Conti, 2017, Clinical Characteristics of Diabetes Mellitus and Suicide Risk, Front. Psychiatry, 8, 248999, 10.3389/fpsyt.2017.00040 · DOI
- Amiri, 2018, Body Mass Index and Risk of Suicide: A Systematic Review and Meta-Analysis, J. Affect. Disord., 238, 615, 10.1016/j.jad.2018.05.028 · DOI · Paper page
- Klinitzke, 2013, Obesity and Suicide Risk in Adults—A Systematic Review, J. Affect. Disord., 145, 277, 10.1016/j.jad.2012.07.010 · DOI
- Branco, 2016, Association between Obesity and Suicide in Woman, but Not in Man: A Population-Based Study of Young Adults, Psychol. Health Med., 22, 275, 10.1080/13548506.2016.1164870 · DOI
- Ju, Y.J., Han, K.T., Lee, T.H., Kim, W., Park, J.H., and Park, E.C. (2016). Association between Weight Control Failure and Suicidal Ideation in Overweight and Obese Adults: A Cross-Sectional Study. BMC Public. Health, 16. · DOI
- Klein, 2021, Suicidality Risk of Newer Antiseizure Medications: A Meta-Analysis, JAMA Neurol., 78, 1118, 10.1001/jamaneurol.2021.2480 · DOI
- Mula, 2013, Antiepileptic Drugs and Suicidality: An Expert Consensus Statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology, Epilepsia, 54, 199, 10.1111/j.1528-1167.2012.03688.x · DOI · Paper page
- Bell, 2009, Suicidality in People Taking Antiepileptic Drugs What Is the Evidence?, CNS Drugs, 23, 281, 10.2165/00023210-200923040-00002 · DOI
- Mula, 2022, Suicidality and Antiepileptic Drugs in People with Epilepsy: An Update, Expert Rev. Neurother., 22, 405, 10.1080/14737175.2022.2064744 · DOI
- Pop, G., Farcaș, A., Butucă, A., Morgovan, C., Arseniu, A.M., Pumnea, M., Teodoru, M., and Gligor, F.G. (2022). Post-Marketing Surveillance of Statins—A Descriptive Analysis of Psychiatric Adverse Reactions in EudraVigilance. Pharmaceuticals, 15. · DOI
- Fong, 2022, Association of Suicidal Ideation and Depression with the Use of Proton Pump Inhibitors in Adults: A Cross-Sectional Study, Sci. Rep., 12, 19539, 10.1038/s41598-022-24244-z · DOI
- Mamdani, 2019, Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide, JAMA Netw. Open, 2, e1913304, 10.1001/jamanetworkopen.2019.13304 · doi:10.1001/jamanetworkopen.2019.13304
- Herdeiro, 2005, Physicians’ Attitudes and Adverse Drug Reaction Reporting A Case-Control Study in Portugal, Drug Saf., 28, 825, 10.2165/00002018-200528090-00007 · DOI · Paper page
- Herdeiro, 2009, Determinants of Under-Reporting of Adverse Drug Reactions A Systematic Review, Drug Saf., 32, 19, 10.2165/00002018-200932010-00002 · DOI · Paper page
- Costa, 2023, Factors Associated with Underreporting of Adverse Drug Reactions by Health Care Professionals: A Systematic Review Update, Drug Saf., 46, 625, 10.1007/s40264-023-01302-7 · DOI
- Goldman, 1998, Limitations and Strengths of Spontaneous Reports Data, Clin. Ther., 20, C40, 10.1016/S0149-2918(98)80007-6 · DOI · Paper page
- Ferrajolo, 2014, Pediatric Drug Safety Surveillance in Italian Pharmacovigilance Network: An Overview of Adverse Drug Reactions in the Years 2001–2012, Expert Opin. Drug Saf., 13, 939581, 10.1517/14740338.2014.939581 · DOI
- Ferrajolo, C., Arcoraci, V., Sullo, M.G., Rafaniello, C., Sportiello, L., Ferrara, R., Cannata, A., Pagliaro, C., Tari, M.G., and Patrizio Caputi, A. (2014). Pattern of Statin Use in Southern Italian Primary Care: Can Prescription Databases Be Used for Monitoring Long-Term Adherence to the Treatment?. PLoS ONE, 9. · DOI
Cited by
Wadden, T. A., Brown, G. K., Egebjerg, C., Frenkel, O., Goldman, B., Kushner, R. F., McGowan, B., Overvad, M., & Fink-Jensen, A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.4346 · Cited by 96
Shapiro, S. B., Yin, H., Yu, O. H. Y., Rej, S., Suissa, S., & Azoulay, L. (2025) · BMJ · doi:10.1136/bmj-2024-080679 · Cited by 49
Hurtado, I., Robles, C., Peiró, S., García-Sempere, A., & Sanfélix-Gimeno, G. (2024) · Diabetologia · doi:10.1007/s00125-024-06243-z · Cited by 45
Bushi, G., Khatib, M. N., Rohilla, S., Singh, M. P., Uniyal, N., Ballal, S., Bansal, P., Bhopte, K., Gupta, M., Gaidhane, A. M., et al. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70037 · Cited by 27
Anatriello, A., Liguori, V., Cagnotta, C., Pentella, C., Scavone, C., Capuano, A., & Rinaldi, B. (2026) · Frontiers in pharmacology · doi:10.3389/fphar.2026.1808359 · Cited by 3
Self-citation
Metadata
- Authors
- Ruggiero, R., Mascolo, A., Spezzaferri, A., Carpentieri, C., Torella, D., Sportiello, L., Rossi, F., Paolisso, G., & Capuano, A.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2024-01-23
- Volume
- 17
- Issue
- 2
- Pages
- 147
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W4391141493
- Cited by
- 55
- References
- 10
- FWCI
- 41.41
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Italian Medicine Agency (AIFA) (B61G17000170005)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.